Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus

Cancer Research

Volumn 70, Issue 19, 2010, Pages 7620-7629

  Mühlebach, Michael D ^a   Schaser, Thomas ^a   Zimmermann, Martina ^b   Armeanu, Sorin ^b   Hanschmann, Kay Martin O ^a   Cattaneo, Roberto ^c   Bitzer, Michael ^b   Lauer, Ulrich M ^b   Cichutek, Klaus ^a   Buchholz, Christian J ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE; GELATINASE A; ONCOLYTIC VIRUS; PLASMINOGEN ACTIVATOR; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; LIVER CANCER; LIVER CELL; MEASLES VIRUS; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; ENZYME ACTIVATION; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASES; MEASLES VIRUS; ONCOLYTIC VIROTHERAPY; PEPTIDE HYDROLASES; TRANSFECTION; VERO CELLS; VIRAL FUSION PROTEINS;

EID: 77957356444     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4650     Document Type: Article

References (38)

1. Yamada H, Katoh H, Kondo S, Okushiba S, Morikawa T. Repeat hepatectomy for recurrent hepatic metastases from colorectal cancer. Hepatogastroenterology 2001;48:828-30.
2. Marti J, Modolo MM, Fuster J, et al. Prognostic factors and time-related changes influence results of colorectal liver metastases surgical treatment: a single-center analysis. World J Gastroenterol 2009;15:2587-94.
3. Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology 2000;32:233-8.
4. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008;6:529-40.
5. Pandha H, Melcher A, Harrington K, Vile R. Oncolytic viruses: time to compare, contrast, and combine? 5th international meeting on replicating oncolytic virus therapeutics. Banff, Alberta, Canada, 18-22 March 2009. Mol Ther 2009;17:934-5.
6. Blechacz B, Splinter PL, Greiner S, et al. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 2006;44:1465-77.
7. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004;64:4919-26.
8. Leonard VH, Sinn PL, Hodge G, et al. Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J Clin Invest 2008;118:2448-58.
9. Vongpunsawad S, Oezgun N, Braun W, Cattaneo R. Selectively receptor-blind measles viruses: identification of residues necessary for SLAM- or CD46-induced fusion and their localisation on a new hemagglutinin structural model. J Virol 2004;78:302-13.
10. Hartl I, Schneider RM, Sun Y, et al. Library-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells. Gene Ther 2005;12:918-26.
11. Schneider RM, Medvedovska Y, Hartl I, et al. Directed evolution of retroviruses activatable by tumour-associated matrix metalloproteases. Gene Ther 2003;10:1370-80.
12. Springfeld C, von Messling V, Frenzke M, et al. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res 2006;66:7694-700.
13. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25:9-34.
14. Cremoux DE, Grandin P, Dieras L, et al. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients. Anticancer Res 2009;29:1475-82.
15. Ulisse S, Baldini E, Sorrenti S, D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 2009;9:32-71.
16. Musso O, Theret N, Campion JP, et al. In situ detection of matrix metalloproteinase-2 (MMP2) and the metalloproteinase inhibitor TIMP2 transcripts in human primary hepatocellular carcinoma and in liver metastasis. J Hepatol 1997;26:593-605.
17. Theret N, Musso O, L'Helgoualc'h A, Campion JP, Clement B. Differential expression and origin of membrane-type 1 and 2 matrix metalloproteinases (MT-MMPs) in association with MMP2 activation in injured human livers. Am J Pathol 1998;153:945-54.
18. Theret N, Musso O, Turlin B, et al. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 2001;34:82-8.
19. Waas ET, Wobbes T, Lomme RM, et al. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg 2003;90:1556-64.
20. Inuzuka K, Ogata Y, Nagase H, Shirouzu K. Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. J Surg Res 2000;93:211-8.
21. Kim TD, Song KS, Li G, et al. Activity and expression of urokinasetype plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 2006;6:211.
22. Cathomen T, Buchholz CJ, Spielhofer P, Cattaneo R. Preferential initiation at the second AUG of the measles virus F mRNA: a role for the long untranslated region. Virology 1995;214:628-32.
23. Radecke F, Spielhofer P, Schneider H, et al. Rescue of measles viruses from cloned DNA. EMBO J 1995;14:5773-84.
24. Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn-Schmiedeberg's Arch Exp Pathol Pharmakol 1931;162:480-3.
25. Zimmermann M, Armeanu S, Smirnow I, et al. Human precisioncut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses. Int J Oncol 2009;34:1247-56.
26. Plumet S, Gerlier D. Optimized SYBR green real-time PCR assay to quantify the absolute copy number of measles virus RNAs using gene specific primers. J Virol Methods 2005;128:79-87.
27. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993;268:10425-32.
28. Hasegawa K, Hu C, Nakamura T, et al. Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol 2007;81:13149-57.
29. Mrkic B, Pavlovic J, Rulicke T, et al. Measles virus spread and pathogenesis in genetically modified mice. J Virol 1998;72:7420-7.
30. Mrkic B, Odermatt B, Klein MA, et al. Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice. J Virol 2000;74:1364-72.
31. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001;86:324-33.
32. Nishida Y, Miyamori H, Thompson EW, et al. Activation of matrix metalloproteinase-2 (MMP-2) by membrane type 1 matrix metalloproteinase through an artificial receptor for proMMP-2 generates active MMP-2. Cancer Res 2008;68:9096-104.
33. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-5.
34. Han YP, Yan C, Zhou L, Qin L, Tsukamoto H. A matrix metalloproteinase-9 activation cascade by hepatic stellate cells in trans-differentiation in the three-dimensional extracellular matrix. J Biol Chem 2007;282:12928-39.
35. Han YP. Matrix metalloproteinases, the pros and cons, in liver fibrosis. J Gastroenterol Hepatol 2006;21 Suppl 3:S88-91.
36. Roeb E, Dietrich CG, Winograd R, et al. Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma differential activity of matrix metalloproteinase-9. Cancer 2001;92:2680-91.
37. Devy L, Huang L, Naa L, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 2009;69:1517-26.
38. Kridel SJ, Sawai H, Ratnikov BI, et al. A unique substrate binding mode discriminates membrane type-1 matrix metalloproteinase from other matrix metalloproteinases. J Biol Chem 2002;277:23788-93.